Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pharmacist Follow-up, a Qualitative Study of Patient Experience

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Hospital Pharmacy of North Norway Trust.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
University of Tromso
Information provided by:
Hospital Pharmacy of North Norway Trust
ClinicalTrials.gov Identifier:
NCT01131715
First received: April 30, 2010
Last updated: May 26, 2010
Last verified: May 2010

April 30, 2010
May 26, 2010
March 2010
July 2010   (final data collection date for primary outcome measure)
Qualitative evaluation of the impact of pharmacist follow-up via interviews with the participating patients [ Time Frame: 3 months or 1 year ] [ Designated as safety issue: No ]
In the pharmacist follow-up procedure under development, patients have individual "consultations" with a pharmacist three times. Patients are recruited to this study at the second or third consultation. Interviews will be performed with patients included to explore how patients' experience this follow-up procedure. Outcome measures from patient interviews can be counted. In qualitative research, the content of the interviews are thoroughly analysed with focus on the meaning of the informant's/interviewee's sayings. Outcomes will be presented as overall themes touched by the informants.
Same as current
Complete list of historical versions of study NCT01131715 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pharmacist Follow-up, a Qualitative Study of Patient Experience
Pharmacist Follow-up of Patients With Coronary Heart Disease. A Qualitative Study of Patient Experience.

A pharmacist follow-up procedure is under development. Patients with coronary heart disease (CHD) is being followed up by a pharmacist for one year with three meetings; at discharge from hospital, after three months and after one year. The evaluation is basically based on quantitative measures as achievement of therapeutic goals, number of drug related problems detected, hospitalisations etc. However, the patients' own experience with the follow-up procedure cannot be evaluated using these measures. Thus, a qualitative approach is needed. In this study, a total of four patients participating in the follow-up will be included and interviewed. A semistructured interview guide will be used. Interviews will be taped, transcribed and analyzed with the intention to explore how patients experience the follow-up from the pharmacist. A thoruough content analysis will be performed. Patients included must have met the pharmacist at least twice. The pharmacist in charge of the follow-up will recruit patients and hand out study information. Patients will reply to the principal investigator of the study and thus kept anonymous for the pharmacist in charge of the follow-up. No pressure will be put on the patients to join, but it will be emphasized that it will help evaluating the procedure.

Not Provided
Observational
Not Provided
Not Provided
Not Provided
Non-Probability Sample

Patients included in the study "Pharmacist follow-up of patients with CHD".

  • Patient Satisfaction
  • Patient Preference
Not Provided
Study group
Patients who are included in the pharmacist follow-up procedure
Garcia BH, Storli SL, Småbrekke L. A pharmacist-led follow-up program for patients with coronary heart disease in North Norway--a qualitative study exploring patient experiences. BMC Res Notes. 2014 Mar 29;7:197. doi: 10.1186/1756-0500-7-197.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
4
July 2010
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • must have met the pharmacist at least twice
  • living within the area of Tromsoe city so that interviews are possible

Exclusion Criteria

  • none as patients are already enrolled in another study
Both
18 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT01131715
SHAN-002
No
Lars Smaabrekke, University of Tromsø
Hospital Pharmacy of North Norway Trust
University of Tromso
Principal Investigator: Lars Smaabrekke, PhD University of Tromso
Study Chair: Beate H Garcia, PhDstudent Hospital Pharmacy of North Norway Trust
Hospital Pharmacy of North Norway Trust
May 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP